These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 18054737

  • 1. New hepatic targets for glycaemic control in diabetes.
    Agius L.
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):587-605. PubMed ID: 18054737
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological regulation of hepatic glucose production.
    Link JT.
    Curr Opin Investig Drugs; 2003 Apr; 4(4):421-9. PubMed ID: 12808881
    [Abstract] [Full Text] [Related]

  • 3. Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes.
    van Poelje PD, Potter SC, Erion MD.
    Handb Exp Pharmacol; 2011 Apr; (203):279-301. PubMed ID: 21484576
    [Abstract] [Full Text] [Related]

  • 4. CS-917, a fructose 1,6-bisphosphatase inhibitor, improves postprandial hyperglycemia after meal loading in non-obese type 2 diabetic Goto-Kakizaki rats.
    Yoshida T, Okuno A, Izumi M, Takahashi K, Hagisawa Y, Ohsumi J, Fujiwara T.
    Eur J Pharmacol; 2008 Dec 28; 601(1-3):192-7. PubMed ID: 19014931
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats.
    van Poelje PD, Potter SC, Chandramouli VC, Landau BR, Dang Q, Erion MD.
    Diabetes; 2006 Jun 28; 55(6):1747-54. PubMed ID: 16731838
    [Abstract] [Full Text] [Related]

  • 6. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.
    Dang Q, Kasibhatla SR, Reddy KR, Jiang T, Reddy MR, Potter SC, Fujitaki JM, van Poelje PD, Huang J, Lipscomb WN, Erion MD.
    J Am Chem Soc; 2007 Dec 19; 129(50):15491-502. PubMed ID: 18041834
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Glucose toxicity is responsible for the development of impaired regulation of endogenous glucose production and hepatic glucokinase in Zucker diabetic fatty rats.
    Fujimoto Y, Torres TP, Donahue EP, Shiota M.
    Diabetes; 2006 Sep 19; 55(9):2479-90. PubMed ID: 16936196
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction.
    Baker DJ, Greenhaff PL, MacInnes A, Timmons JA.
    Diabetes; 2006 Jun 19; 55(6):1855-61. PubMed ID: 16731853
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Discovery of fructose-1,6-bisphosphatase inhibitors for the treatment of type 2 diabetes.
    van Poelje PD, Dang Q, Erion MD.
    Curr Opin Drug Discov Devel; 2007 Jul 19; 10(4):430-7. PubMed ID: 17659484
    [Abstract] [Full Text] [Related]

  • 14. Prolonged inhibition of glycogen phosphorylase in livers of Zucker Diabetic Fatty rats models human glycogen storage diseases.
    Floettmann E, Gregory L, Teague J, Myatt J, Hammond C, Poucher SM, Jones HB.
    Toxicol Pathol; 2010 Apr 19; 38(3):393-401. PubMed ID: 20215584
    [Abstract] [Full Text] [Related]

  • 15. Novel therapeutics based on inhibiting the interaction of glycogen phosphorylase and GL-subunit of glycogen-associated protein phosphatase 1: WO2009127723.
    Zhang L, Liu H.
    Expert Opin Ther Pat; 2010 Jul 19; 20(7):969-73. PubMed ID: 20367521
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Glucokinase and molecular aspects of liver glycogen metabolism.
    Agius L.
    Biochem J; 2008 Aug 15; 414(1):1-18. PubMed ID: 18651836
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy.
    McCormack JG, Westergaard N, Kristiansen M, Brand CL, Lau J.
    Curr Pharm Des; 2001 Sep 15; 7(14):1451-74. PubMed ID: 11529255
    [Abstract] [Full Text] [Related]

  • 19. Increased glucose production in mice overexpressing human fructose-1,6-bisphosphatase in the liver.
    Visinoni S, Fam BC, Blair A, Rantzau C, Lamont BJ, Bouwman R, Watt MJ, Proietto J, Favaloro JM, Andrikopoulos S.
    Am J Physiol Endocrinol Metab; 2008 Nov 15; 295(5):E1132-41. PubMed ID: 18780768
    [Abstract] [Full Text] [Related]

  • 20. Advances in glycogen phosphorylase inhibitor design.
    Oikonomakos NG, Somsák L.
    Curr Opin Investig Drugs; 2008 Apr 15; 9(4):379-95. PubMed ID: 18393105
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.